Psomagen

Psomagen has been committed to personalized genomic services and the implementation of sequencing technology at an early stage in recent years. Psomagen is enhancing its R&D efforts to bring genetic information to the individual level. By refining the analysis of genes and genomes, its services can better identify the unique differences between a patient’s genetics, environment, and lifestyle. This research allows Psomagen to generate data that helps predict disease risks as well as aids in diagnosing and recommending treatment methods tailored to individuals. To support both the research and clinical aspects of personalized medicine, Psomagen’s whole-genome and whole-exome sequencing processes have received rigorous certification through CLIA (Clinical Laboratory Improvement Amendments) and CAP (College of American Pathologists). CLIA is the U.S. accreditation standard coordinated by the Centers for Medicare & Medicaid Services (CMS). The process verifies the accuracy and reliability of clinical sequencing used for diagnosis, prevention, and treatment of diseases. The company is at the forefront of genetic and genomic analysis. Engaged in researching precision medicine and biotechnology solutions, Psomagen serves over 18,000 research clients across 153 countries worldwide.